Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Jul;82(1):370–372. doi: 10.1172/JCI113598

HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.

T P Miller 1, S M Lippman 1, C M Spier 1, D J Slymen 1, T M Grogan 1
PMCID: PMC303519  PMID: 3392214

Abstract

The clinical utility for establishing the immune phenotype in patients with non-Hodgkin's lymphoma is controversial. To help resolve this dilemma, we studied 104 consecutive patients with diffuse large cell lymphoma, the most common subtype of potentially curable non-Hodgkin's lymphomas. The presence or absence of the human class II histocompatibility antigen was determined using the monoclonal antibody anti-HLA-DR (Ia), and the results correlated with pretreatment clinical features and survival. We found that eight HLA-DR negative patients had similar pretreatment clinical characteristics compared with 96 HLA-DR positive patients, but HLA-DR negative patients had a significantly shorter survival duration compared with HLA-DR positive patients (P = 0.003 log-rank). The median survival of the HLA-DR negative patients was 0.5 years compared to 2.8 yr for the HLA-DR positive patients. No HLA-DR negative patient survived beyond 1.5 yr. A multi-variate analysis, adjusting for prognostic factors of known clinical significance, confirmed the importance of HLA-DR as a prognostic factor (P = 0.016). We conclude that determining the presence of HLA-DR is a relatively simple pretreatment study that identifies a small but important group of patients who are not curable using currently available combination chemotherapy.

Full text

PDF
370

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brouet J. C., Rabian C., Gisselbrecht C., Flandrin G. Clinical and immunological study of non-Hodgkin T-cell lymphomas (cutaneous and lymphoblastic lymphomas excluded). Br J Haematol. 1984 Jun;57(2):315–327. doi: 10.1111/j.1365-2141.1984.tb02901.x. [DOI] [PubMed] [Google Scholar]
  2. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  3. Clayberger C., Wright A., Medeiros L. J., Koller T. D., Link M. P., Smith S. D., Warnke R. A., Krensky A. M. Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet. 1987 Sep 5;2(8558):533–536. doi: 10.1016/s0140-6736(87)92924-2. [DOI] [PubMed] [Google Scholar]
  4. Cossman J., Jaffe E. S., Fisher R. I. Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features. Cancer. 1984 Oct 1;54(7):1310–1317. doi: 10.1002/1097-0142(19841001)54:7<1310::aid-cncr2820540714>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  5. Fisher R. I., Miller T. P., Dana B. W., Jones S. E., Dahlberg S., Coltman C. A., Jr Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987 Apr;24(2 Suppl 1):21–25. [PubMed] [Google Scholar]
  6. Gerdes J., Stein H., Pileri S., Rivano M. T., Gobbi M., Ralfkiaer E., Nielsen K. M., Pallesen G., Bartels H., Palestro G. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet. 1987 Aug 22;2(8556):448–449. doi: 10.1016/s0140-6736(87)90977-9. [DOI] [PubMed] [Google Scholar]
  7. Greer J. P., York J. C., Cousar J. B., Mitchell R. T., Flexner J. M., Collins R. D., Stein R. S. Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. J Clin Oncol. 1984 Jul;2(7):788–798. doi: 10.1200/JCO.1984.2.7.788. [DOI] [PubMed] [Google Scholar]
  8. Greiner J. W., Hand P. H., Colcher D., Weeks M., Thor A., Noguchi P., Pestka S., Schlom J. Modulation of human tumor antigen expression. J Lab Clin Med. 1987 Mar;109(3):244–261. [PubMed] [Google Scholar]
  9. Grogan T. M., Fielder K., Rangel C., Jolley C. J., Wirt D. P., Hicks M. J., Miller T. P., Brooks R., Greenberg B., Jones S. Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. Am J Clin Pathol. 1985 Mar;83(3):279–288. doi: 10.1093/ajcp/83.3.279. [DOI] [PubMed] [Google Scholar]
  10. Grogan T. M., Lippman S. M., Spier C. M., Slymen D. J., Rybski J. A., Rangel C. S., Richter L. C., Miller T. P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988 Apr;71(4):1157–1160. [PubMed] [Google Scholar]
  11. Habeshaw J. A., Lister T. A., Stansfeld A. G., Greaves M. F. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983 Mar 5;1(8323):498–501. doi: 10.1016/s0140-6736(83)92191-8. [DOI] [PubMed] [Google Scholar]
  12. Horning S. J., Weiss L. M., Crabtree G. S., Warnke R. A. Clinical and phenotypic diversity of T cell lymphomas. Blood. 1986 Jun;67(6):1578–1582. [PubMed] [Google Scholar]
  13. Jones S. E., Fuks Z., Bull M., Kadin M. E., Dorfman R. F., Kaplan H. S., Rosenberg S. A., Kim H. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer. 1973 Apr;31(4):806–823. doi: 10.1002/1097-0142(197304)31:4<806::aid-cncr2820310408>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  14. Levine A. M., Taylor C. R., Schneider D. R., Koehler S. C., Forman S. J., Lichtenstein A., Lukes R. J., Feinstein D. I. Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features. Blood. 1981 Jul;58(1):52–61. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES